- Report
- July 2024
- 182 Pages
Global
From €4090EUR$4,500USD£3,517GBP
- Report
- May 2024
- 182 Pages
Global
From €4090EUR$4,500USD£3,517GBP
- Report
- December 2022
- 115 Pages
Global
From €4090EUR$4,500USD£3,517GBP
- Report
- August 2025
- 188 Pages
Global
From €3222EUR$3,545USD£2,771GBP
€3580EUR$3,939USD£3,079GBP
- Report
- August 2025
- 195 Pages
Global
From €3222EUR$3,545USD£2,771GBP
€3580EUR$3,939USD£3,079GBP
- Report
- August 2025
- 191 Pages
Global
From €3222EUR$3,545USD£2,771GBP
€3580EUR$3,939USD£3,079GBP
- Report
- August 2025
- 186 Pages
Global
From €3222EUR$3,545USD£2,771GBP
€3580EUR$3,939USD£3,079GBP
- Report
- December 2024
- 200 Pages
Global
From €3409EUR$3,750USD£2,931GBP
- Report
- May 2024
- 200 Pages
Global
From €3772EUR$4,150USD£3,243GBP
- Report
- March 2024
- 200 Pages
Global
From €3772EUR$4,150USD£3,243GBP
- Report
- January 2024
- 200 Pages
Global
From €3772EUR$4,150USD£3,243GBP
- Report
- January 2024
- 200 Pages
Global
From €3772EUR$4,150USD£3,243GBP
- Report
- June 2025
- 400 Pages
Global
From €4499EUR$4,949USD£3,868GBP
- Report
- February 2024
- 179 Pages
Global
From €2727EUR$3,000USD£2,345GBP
- Report
- July 2023
- 115 Pages
Global
From €4090EUR$4,500USD£3,517GBP
- Drug Pipelines
- April 2025
- 280 Pages
Global
From €2727EUR$3,000USD£2,345GBP
- Drug Pipelines
- July 2025
- 280 Pages
Global
From €2727EUR$3,000USD£2,345GBP
- Drug Pipelines
- April 2025
- 204 Pages
Global
From €2727EUR$3,000USD£2,345GBP
- Report
- October 2022
- 200 Pages
Global
From €2681EUR$2,950USD£2,306GBP
- Report
- June 2026
- 115 Pages
Mexico
From €2726EUR$2,999USD£2,344GBP

The Antisense Oligonucleotide market is a segment of the biotechnology industry that focuses on the development of drugs that use short strands of nucleic acids to target and inhibit the expression of specific genes. These drugs are used to treat a variety of diseases, including cancer, cardiovascular disease, and neurological disorders. Antisense oligonucleotides are designed to bind to a specific mRNA sequence, blocking the translation of the gene into a protein. This technology has the potential to revolutionize the treatment of many diseases, as it can be used to target specific genes without affecting other parts of the body.
The Antisense Oligonucleotide market is highly competitive, with many companies developing and marketing their own products. Some of the major players in the market include Alnylam Pharmaceuticals, Ionis Pharmaceuticals, and Arrowhead Pharmaceuticals. Other companies in the market include Regulus Therapeutics, Dicerna Pharmaceuticals, and Quark Pharmaceuticals. Show Less Read more